USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Glaxosmithkline Biologicals Sa

USPTO PatentsView assignee record - 436 granted patents across 31 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

436

Total patents granted

CPC technology areas

17.7

Avg claims per patent

-10%

5-year filing velocity

The verdict

Glaxosmithkline holds 436 US patents across 31 technology areas, rank #1,007 of 50,000 tracked assignees.

#1,007
of 50,000 US assignees by volume: Top 5%
by Innovation Score (58.3/100): 17.7
avg claims per patent: -10%
filing velocity, last 5 yrs

Portfolio overview

Glaxosmithkline Biologicals Sa has been granted 436 US utility patents between 2015 and 2025, placing Glaxosmithkline Biologicals Sa at rank #1,007 across all assignees tracked by PlainPatent. This portfolio spans 31 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.7 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Glaxosmithkline Biologicals Sa is one of the more focused assignees in the PatentsView dataset. By volume, Glaxosmithkline sits between Nuvoton Technology Corporation (438 patents, rank #1,003) and National Chiao Tung University (434 patents, rank #1,011) - the closest US assignees by grant volume. The composite Innovation Score of 58.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 206 grants, compared with 230 in the 2015–2019 window, a -10% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Glaxosmithkline Biologicals Sa's 17.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 31 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Glaxosmithkline Biologicals Sa against peers pursuing similar technology classes.

Nuvoton Technology

438
Advantest

437
Block

437
Harris

437
Glaxosmithkline B… ◀

436
Ferrari S p A

435
Hansgrohe SE

435
Akamai

434
National Chiao Tu…

434

What this shows Glaxosmithkline holds 436 patents at rank #1,007, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Glaxosmithkline

By rank, the assignees closest to #1,007 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Glaxosmithkline's primary technology class.

Glaxosmithkline's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

58 Top 5% higher than 95% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Glaxosmithkline Biologicals Sa patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	35	8.0%
2016	57	13.1%
2017	54	12.4%
2018	37	8.5%
2019	47	10.8%
2020	38	8.7%
2021	32	7.3%
2022	34	7.8%
2023	52	11.9%
2024	37	8.5%
2025	13	3.0%

Which technologies does Glaxosmithkline Biologicals Sa patent most?

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 409

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 341

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 212

C07K - PEPTIDES 200

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 180

C08B - POLYSACCHARIDES; DERIVATIVES THEREOF 23

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 23

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 22

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 18

Y10S - TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS 15

C12Y - ENZYMES 15

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 7

C12R - INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS 6

B01D - SEPARATION 6

C07D - HETEROCYCLIC COMPOUNDS 6

Top 15 of 31 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Multi-domain

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#1,007

Across all tracked assignees

Innovation Score

58.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Glaxosmithkline Biologicals Sa hold?

Glaxosmithkline Biologicals Sa holds 436 US granted patents filed between 2015 and 2025, spanning 31 technology areas.

What is Glaxosmithkline Biologicals Sa's Innovation Score?

Glaxosmithkline Biologicals Sa has an Innovation Score of 58.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Glaxosmithkline Biologicals Sa focus on?

Glaxosmithkline Biologicals Sa's top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 409 patents. The company has filed patents in 31 CPC subclasses total.

Is Glaxosmithkline Biologicals Sa's patent filing rate increasing or decreasing?

Glaxosmithkline Biologicals Sa's recent filing velocity is -10% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Glaxosmithkline Biologicals Sa's patents?

Glaxosmithkline Biologicals Sa's patents average 17.7 claims each. This falls within the standard range, providing solid legal coverage.

How is the Glaxosmithkline Biologicals Sa patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Glaxosmithkline's 436 grants land it in the top 5% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Glaxosmithkline ranks #1,007 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.